Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed Inc. (ELMD) specializes in advanced airway clearance solutions through its clinically validated SmartVest system. This dedicated news hub provides investors and healthcare stakeholders with essential updates on respiratory care innovations, regulatory compliance, and corporate developments.
Find authoritative coverage of ELMD's progress in HFCWO technology, including product enhancements, partnership announcements, and quality certifications. Our curated news selection emphasizes factual reporting on clinical trial outcomes and market expansion initiatives within the medical device sector.
Regular updates include earnings disclosures, manufacturing quality milestones, and research collaborations. Bookmark this resource for streamlined access to verified ELMD developments that impact respiratory therapy standards and investment considerations.
Electromed (NYSE American: ELMD) announced that Summers Value Partners intends to nominate four candidates for election to the Board of Directors at the upcoming Fiscal 2022 Annual Meeting of Shareholders. The Board is currently engaged in discussions with Summers Value Partners to evaluate the nominees, focusing on shareholder interests. With insiders owning over 16% of Electromed's shares, their interests align closely with those of the shareholders. A proxy statement detailing the Board's recommendations will be filed with the SEC and distributed to eligible shareholders.
Electromed, Inc. (NYSE American: ELMD) announced preliminary Q4 FY 2021 financial results, projecting net revenue of $9.3 to $9.5 million, a 37% increase from $6.9 million in Q4 FY 2020. Operating income is expected to be between $0.5 and $0.7 million, down from $1.3 million the previous year, which included $0.9 million from government stimulus. The company reported $11.9 million in cash with no debt. Management indicated that a recent data security incident did not materially impact financial results for the quarter, affirming strong performance despite pandemic challenges.
Electromed, a leader in airway clearance technologies (NYSE American: ELMD), announced participation in Canaccord Genuity’s 41st Annual Growth Conference, scheduled for August 10-12, 2021. The group presentation will take place on August 11, 2021, at 10:00 AM Eastern Time. Attendees can access the webcast through a link provided in the press release or via the Investor Relations section of Electromed’s website. The company specializes in airway clearance therapy products, including the SmartVest Airway Clearance System, and was founded in 1992 and is headquartered in New Prague, Minnesota.
Electromed, Inc. (NYSE American: ELMD) has announced a $3.0 million stock repurchase authorization effective May 26, 2021. The company plans to buy back its common stock, with purchases made in open market transactions or through block trades. This move is driven by a strong balance sheet and positive cash flow, reflecting management's belief that the stock is undervalued. The buyback program is set to continue until May 26, 2022, but may be modified or discontinued at any time.
Electromed, Inc. (NYSE American: ELMD) has been recognized as Quality Magazine’s 2021 Plant of the Year. This accolade is based on the 2021 Quality Leadership Top 100 Company survey, which evaluates continuous improvement, quality training, warranty costs, and ISO certifications, including ISO 13485. Electromed has ranked among the top 10 in this survey three times in the last four years. CEO Kathleen Skarvan emphasized the recognition reflects the team's dedication to improving patient lives through high-quality products and services.
Electromed, Inc. (NYSE American: ELMD) reported its Q3 FY 2021 financial results, revealing a 0.5% increase in net revenue to $8.8 million, driven by a 4.2% rise in home care revenue. The gross profit percentage improved to 76.3% of net revenue. However, net income fell to $224,000 or $0.03 per diluted share, down from $653,000 or $0.07 in Q3 FY 2020, mainly due to increased investments in R&D and SG&A. Cash at March 31, 2021 stood at $12.5 million, supported by $834,000 in operating cash flow. Despite challenges from COVID-19, management expressed optimism for ongoing recovery.
Electromed, Inc. (NYSE American: ELMD) is set to release its fiscal 2021 third quarter financial results on May 11, 2021, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss these results. Interested participants can join by calling (877) 407-9753 for domestic calls and (201) 493-6739 for international calls. A live webcast will be accessible via Electromed’s Investor Relations website, and a replay will also be available online post-event.
Electromed, Inc. (NYSE American: ELMD) announced that Kathleen Skarvan, President and CEO, and Mike MacCourt, CFO, will participate in the Sidoti Spring 2021 Virtual Investor Conference on March 24-25, 2021. They will be available for one-on-one meetings during both days. Electromed specializes in airway clearance technology, manufacturing products like the SmartVest® Airway Clearance System, aiding patients with impaired pulmonary function. The group presentation is scheduled for March 24, 2021, at 2:30 PM Eastern Time. Further details can be found on their website.
Electromed (NYSE American: ELMD) reported a 11.1% increase in net revenue, reaching $9.5 million for Q2 FY 2021, driven by a 16.1% rise in home care revenue to $8.9 million. Gross profit margin improved to 79.2%, up from 78.1% in Q2 FY 2020. Net income remained stable at $1.2 million, translating to $0.13 per diluted share. Despite a 37.4% decline in institutional revenue due to COVID-19's impact, the company maintains a robust cash position of $11.7 million. Management expresses cautious optimism for continued growth in the latter half of FY 2021.
Electromed, Inc. (NYSE American: ELMD) will release its fiscal 2021 second quarter financial results on February 9, 2021, after market close. A conference call will follow at 5:00 p.m. ET to discuss the results. Interested participants can join via phone, with domestic and international numbers provided. The call will also be accessible through a live webcast in the Investor Relations section of Electromed's website. The company manufactures airway clearance products, including the SmartVest Airway Clearance System.
